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he genomics revolution, which has seemingly 
pervaded all of the biological and biomedical 
sciences, has brought about its most impressive 
advances in the pharmaceutical sciences. The 
technological advances in high-throughput 
DNA sequencing, in assessing gene expression 
for thousands of transcripts, and in RNA con-
struFcts to silence specific genes have not only 
been the driving force behind genomic studies, but have also 
contributed to an emerging paradigm shift that is occurring 
in pharmacology, drug development, and pharmacothera-
peutics. The molecular tools now readily available to labora-
tories have hastened the shift from drug development based 
largely on chemistry to one based on our growing biologi-
cal knowledge of the physiological and molecular effects of 
compounds.1 It is now becoming possible with these tools to 
assess at the cellular level the nature of drug action, toxicity, 
and tolerance. Similarly, our understanding of human disease 
is being refined, which will lead to more precise therapeutic 
interventions based on more precise understandings of dis-
ease states.
Ironically, the area of genomic-driven advances in phar-
macy that enjoys the most public press is also the area where 
the advances are the least certain. Much has been written 
about the age of personalized medicine where each patient’s 
genetic makeup will determine an individual-specific course of 
drug treatment designed to be the most efficacious and safe. 
Pharmacogenetics, which has been an active area of research 
for over 50 years,2 seeks to provide patients efficacious thera-
peutics with minimal adverse drug reactions based on their 
genetic makeup (genotype) at one or more genes determining 
drug metabolism and/or drug transport (drug metabolism or 
transport pharmacogenetics) or in genes that are the direct 
targets of drug action (drug target pharmacogenetics). The 
literature is extensive, including several new journals detailing 
studies showing gene-drug relationships and the importance 
of including a patient’s genetic makeup in guiding therapeutic 
decision making.3-7 However, a significant portion of this 
body of literature consists of contradictory reports or at the 
least call into question the utility of genetic testing in guid-
ing therapeutic management. For example, one of the most 
studied genes in pharmacogenetics, MDR1 (ABCB1), the gene 
that codes for the ubiquitous drug efflux pump, P-glycopro-
tein (P-gp), has so far defied any straightforward consensus 
concerning the importance of genetic polymorphisms in drug 
disposition and response.8 Regarding the pharmacogenetics of 
cytochrome P450 genes (CYP), Nebert and Vesell9 have cau-
tioned that even recent, much lowered estimates of reductions 
in adverse drug reactions of 10% to 20% by the extensive 
genotyping of CYP polymorphisms may be overly optimistic. 
This constant background of contrary data suggests caution 
should be used in assessing the importance of pharmacogenet-
ics in managing drug therapies.10-14 
The many contrary reports, or the authors making them, 
are not suggesting that there is little to be gained by pharma-
cogenetics studies and genetic testing. Rather, this data un-
derscores the complexity of the human genome, the extensive 
genetic diversity among humans, and the nature of gene-gene 
and gene-environment interactions. This paper summarizes 
some of these complexities using two of the more successful 
pharmacogenetic “stories” to highlight the confounding is-
sues involved for all genes that play a role in drug response 
and efficacy.
Prior to considering the complexities of genomes, it is 
first important to reaffirm the role of environmental factors 
in individual variation of drug response. There are many 
environmental factors determining how a given patient will 
respond to a drug including age, gender, diet, as well other 
concurrent drug therapies (Figure 1). These nongenetic factors 
often play a large role in the discrepancies in genotype-pheno-
type studies.13 Assessing the proportion of variation in patient 
response due to environment is absolutely essential before the 
role of genetics can be considered. 
The two pharmacogenetic “success stories” that follow 
are in part successful because the involved compounds pos-
sess two critical properties. These properties are shared by 
most pharmacogenetics success stories.9 The first property is 
one born of the drug itself. Drugs with narrow therapeutic 
windows are more likely to be pharmacogenetically relevant 
since even small, genetically-based differences in patient drug 
metabolism, absorption, distribution, or clearence may result 
in toxicity. Second, for both groups of compounds there ex-
ists at least one critical step in the drug response pathway 
controlled principally by a single gene—the phenotype is 
said to be monogenic. Drugs that are metabolized by many 
genes, or for which there are multiple alternate pathways, are 
unlikely to elicit varying responses due to polymorphisms in a 
single gene—the phenotype is said to be polygenic. Similarly, 
in the same sense that multiple genes lessen the importance 
of any one gene in patient response, multiple polymorphisms 
within one gene will tend to lessen the utility of pharmacoge-
netic studies. The pharmacogenetics of a system can become 
confusing if the gene responsible for the phenotype has many 
polymorphisms, all with the similar phenotypic outcomes (re-
ferred to as allelic heterogeneity). In such cases, the utility of a 
single genetic test to guide dosing is small if it is predictive for 
only a limited subset of patients.
The two examples described here are the pharmacogenet-
ics of thiopurines and warfarin. These compounds both have 
narrow therapeutic windows and have phenotypes that are 
determined by one or two genes. They have both been noted 
repeatedly as classic examples of the important role pharmaco-
genetics will play in explaining variation in patient response. 
T
Figure 1_Many factors, both environmental, patient-specific, and 
genetic may determine how an individual will respond to a therapeu-
tic agent. Pharmacogenetics seeks to identify that portion of variation 
in response due to genetic differences among humans.
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We will use them here to elucidate other features of both 
drugs and genetics that are important in understanding the 
limitations and complexities of pharmacogenetics.
Pharmacogenetics of Thiopurine 
S-methyltransferase (TPMT) 
Thiopurines are among the first line treatments for child-
hood acute lymphoblastic leukemia (ALL), organ transplant 
recipients, inflammatory bowel disease, and autoimmune 
diseases.14 Thiopurine S-methyltransferase catalyzes the S-
methylation of a number of chemotherapeutic prodrugs such 
as 6-mercaptopurine (6-MP), 6-thioguanine (6-TG), and aza-
thiopurine (AZA). In the cell, 6-MP and AZA are converted 
into thioinosine monophosphate (TIMP) and ultimately into 
thioguanosine monophosphate (TGMP). TGMP is ultimately 
converted into cytotoxic nucleotide analogs (TGN), which in-
hibits DNA and RNA synthesis. The S-methylation of 6-MP 
to methylmercaptopurine (meMP) is an inactivation pathway 
leading to the ultimate clearance of 6-MP and 6-TG (Figure 
2). High TGN accumulation has been linked to hematopoi-
etic toxicity and results in low patient tolerance to thiopurine 
therapy. The genetic role of polymorphisms in TPMT and 
resulting enzyme activity was first noted in red blood cells of 
healthy volunteers.16 Three groups were indentified with high, 
intermediate, and low enzyme activities. These three groups 
have now been shown to represent individuals carrying either 
zero, one, or two variant alleles for TPMT. Thus, hematopoi-
etic toxicity, the phenotype of interest, is determined in part 
by a single gene (monogenic). Interestingly, another enzyme, 
Figure 2_The inactive prodrugs, 6-mercaptopurine (6-MP), 6-thioguanine (6-TG), and azathioprine (AZA), are activated by multiple enzymes. 
After uptake, 6-MP and AZA are converted into thioinosine monophosphate (TIMP). 6-TG is converted into thioguanosine monophosphate 
(TGMP). Thiopurine methyltransferase (TPMT) is the major enzyme involved in the inactivation pathway for all three thiopurines to meth-
ylmercaptopurine (meMP), 6-methylmercaptopurine (6-meMPR), methyl-thioguanosine monophosphate (meTGMP), and methy-thioinosine 
monophosphate (meTIMP). Cytotoxic effects of thiopurine drugs occur when cytotoxic nucleotide analogs (TGN) are incorporated into DNA  
or RNA stopping synthesis. Adapted from www.pharmgkb.org/index.jsp.15
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xanthine oxidase (XHD), also plays a role in inactivation of 
thiopurines. However, in hematopoietic tissue, XHD is not 
expressed17 so the polymorphisms that must certainly exist in 
XDH do not confound the phenotypic response of interest; 
namely, hematopoietic toxicity. 
Polymorphisms in TPMT have been shown to play a 
role in explaining individual variation in response to thio-
purine drug therapy. Low TPMT activity is associated with 
hematopoietic toxicity in patients treated with standard 
doses of 6-MP, 6-TG, or AZA.18 Twenty-nine variant al-
leles have been identified in TPMT as of 2008. Of these 
variant alleles, four have been most studied (for review see 
Wang and Weinshilboum19) with regard to their effects on 
decreased TPMT activity—TPMT*2, *3A (most common in 
Caucasians), *3B, and *3C (most common variant in African 
Americans). The most common variant allele, TPMT*3A, 
is associated with low TPMT activity though no differences 
are noted in gene expression compared with the wildtype 
allele.20 TPMT*2 shows loss of catalytic activity though no 
difference in mRNA concentrations.21 The low enzyme activ-
ity observed for both variants is likely due to greater rate of 
degradation.20,22 Most importantly, while other variants have 
been identified (TMPT*4, *5, *6, and *7), they appear to be 
rare and therefore unlikely to confound the relationship be-
tween phenotype and genotype, at least among the popula-
tions studied to date. Note, however, that the four common 
variant alleles do not explain all the side effects associated 
with thiopurine therapy.23 As is often the problem for many 
other pharmacogenetic cases, there are other variant alleles 
for TPMT whose frequencies and, therefore, importance in 
other populations is yet unknown. In a review examining the 
role of genetic variation in TPMT mediated adverse drug re-
actions, van Aken and colleagues found that 78% of the ad-
verse drug reactions could not be accounted for by a limited 
number of polymorphisms generally examined in TPMT.23 
These authors point out the need for further studies identify-
ing additional variant alleles in other ethnic groups and for 
the need for continued careful clinical monitoring of adverse 
drug reactions.
Pharmacogenetics of Warfarin 
Warfarin is a commonly prescribed oral anticoagulant 
for the prevention and treatment of myocardial infarction, 
ischemic stroke, venous thrombosis, and atrial fibrillation. 
Warfarin has a narrow therapeutic window with large inter-
patient variation. Insufficient dosing may prevent throm-
boembolism while over dosing may cause risk of bleeding 
events. Warfarin is a very effective antagonist of the vitamin 
K epoxide reductase complex (VKORC1), a critical enzyme 
in the vitamin K-dependent clotting pathway. Warfarin is 
delivered as a racemic mixture of the R and S stereoisomers. 
The stereoisomers are metabolized by different members  
of the cytochrome P450 phase 1 enzymes. S-warfarin is  
the more potent inhibitor of VKORC1 by 3- to 5-fold and  
accounts for 60% to 70% of the anticoagulation response 
(for review see Yin and Miyata24). This is critical in terms  
of warfarin’s pharmacogenetics since S-warfarin is largely  
metabolized by a single enzyme (CYP2C9) and thus behaves 
as a monogenic trait. In contrast, R-warfarin is metabolized 
by a number of CYP enzymes, mainly CYP3A4, and to a 
lesser degree CYP 1A1, 1A2, 2C8, 2C9, 2C18, and 2C19.  
If R-warfarin were the most active agent, it is unlikely this 
drug would be important pharmacogenetically since with  
so many different genes involved in its metabolism, no single 
set of polymorphisms would be useful predictors of therapeu-
tic outcome. 
 To date, more than 50 variants in CYP2C9 have been 
described in human populations; at least 24 are nonsynony-
mous substitutions resulting in proteins with altered amino 
acids sequences. Two variants, CYP2C9*2 and *3, are the 
most common and most extensively studied. Patients with 
CYP2C9*2 and/or CYP2C9*3 variants metabolize warfarin 
more slowly; thus, traditional dosing regimens may lead to 
bleeding events or longer times to achieve stable drug con-
centrations versus dose during which bleeding events may 
occur. Other polymorphisms that occur at much lower fre-
quencies have not been evaluated. Importantly, frequencies of 
CYP2C9*2 and *3 vary considerably among ethnic popula-
tions. Among Caucasians, *2 and *3 frequencies vary from 
8% to 20% and 6% to 10%, respectively. Unfortunately, in 
respect to their utility as general predictors of patient response 
to warfarin therapy, CYP2C9*2 and *3 are largely absent in 
Asian populations and are rare in African-American popula-
tions with frequencies ranging from 1% to 4%. Once again, 
the distribution of clinically important alleles among human 
populations is important and limits the universal application 
of data gathered from one ethnic group. This problem cannot 
be overstated. The advancements to be derived from pharma-
cogenetics are dependent upon the cataloging of all relevant 
variants in human populations and the development of large- 
scale genetic screening technologies to identify these alleles. 
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There is yet another player in the warfarin pharmaco-
genetics story. The target of warfarin (VKORC1) also has 
variant alleles that affect how patients respond to therapy. 
This is an example of drug target pharmacogenetics, which, 
unlike pharmacogenetics of genes involved in drug metabo-
lism or drug transport, often results in differences in the 
pharmacodynamics of response. Mutations in VKORC1 have 
been identified in vitamin K-deficiency disorders and warfa-
rin resistance. There are at least five important variants for 
VKORC1 as well as numerous, less-common variants. Fortu-
nately, these variants can be grouped into four haplotypes—
chromosomal segments within which the DNA sequence 
is invariant or constant among most human populations. 
These four haplotypes (VKORC1*1, *2, *3, and *4) include 
most of the common SNPs that contribute to interpatient 
variation in warfarin dosing in Caucasians. VKORC1*1 is 
considered the reference sequence and is the likely ancestral 
haplotype. Individuals with the VKORC1*2 haplotype (also 
confusingly referred to as haplotype group A) require lower 
warfarin doses. This haplotype is common in Asians and 
Caucasians and rare in African populations.25 VKORC1*3 
and VKORC1*4 (referred to as haplotype group B) require 
a higher warfarin dose. VKORC1*3 is the most common 
haplotype in African populations and is also common in 
Caucasians. 
Recently, another CYP gene has been identified that 
has a clinically important impact on the ability of patients to 
reach stable warfarin dosing. An allele in CYP4F2 that is at 
moderate frequency in Asians and Caucasians (~30%) though 
low in African-Americans (7%) results in higher warfarin 
doses to stable dosing. Thus, the warfarin story becomes less 
perfect. The metabolic role of CYP4F2 is, as yet, unknown.
Summary
Neither of the two examples presented here is the perfect 
pharmacogenetics story, though they may be the best examples 
to date. Our goal is to highlight these two examples as a 
means of describing some of the problems that are common to 
many pharmacogenetic cases. The pharmacogenetic literature 
contains many examples of confusing, or even contradictory, 
studies that arise due to unknown environmental factors that 
result in poor outcomes; drugs whose metabolism/transport are 
affected by multiple genes in multiple pathways; and clinically 
important genes that have many rare allelic variants with simi-
lar phenotypes variation in the frequencies of allelic variants 
among ethnic groups that mask the role of any one variant.
These issues are common to most gene/drug dynam-
ics and do not preclude the importance of pharmacogenetic 
studies. They do call for more realistic assessments of the 
role of genetic testing for the practicing clinician as this field 
develops. LM
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